Gaithersburg, Maryland – January 2, 2018: MaxCyte announced today that Debra K. Bowes, Executive Vice President, Business and Strategic Development, will present at two life sciences conferences this month: the Biotech Showcase on January 8 at 3:30 p.m. Pacific Time (Hotel Union Square, San Francisco) and Phacilitate Immuno-Oncology Frontiers World on January 23 (Hyatt Regency, Miami, FL) at 2:50 p.m. Eastern Time.
Ms. Bowes will present and discuss MaxCyte’s next-generation autologous CAR (chimeric antigen receptor) therapies. In her presentation, Ms. Bowes will focus on how MaxCyte’s breakthrough immuno-oncology CAR therapeutic platform has the ability to engineer transient persistence to mitigate off-tumor toxicity and significantly reduce the turnaround time of autologous cell therapy to patients.
“We are delighted to share the remarkable progress we’ve made with our novel and proprietary CAR platform and CAR therapies for a broad range of targets and cancers – including solid tumors, while reducing potential adverse events that have plagued previous CAR technologies,” said Doug Doerfler, MaxCyte President & CEO. “Our goal is to advance our first CAR therapy into the clinic in the first half of the new year, and we are excited to have a forum to share our new and upcoming developments at two conferences this month.”
More information on the conferences can be found at //ebdgroup.knect365.com/biotech-showcase/ for Biotech Showcase and at www.iofrontiersworld.com/immuno-oncology-frontiers-world-agenda for Phacilitate Immuno-Oncology Frontiers World.
MaxCyte is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte’s team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company’s cell-engineering platform is FDA-accredited, providing MaxCyte’s customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also an early-stage drug development company developing CAR therapies via its proprietary platform in immuno-oncology, which allows for development of novel virus-free CAR therapies targeting a broad range of cancers with controlled persistence. For more information, visit /.